Pubblicazioni

• Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
• MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis
• Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
• COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
• Signs and symptoms of COVID-19 in patients with multiple sclerosis
• Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
• SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
• Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience
• Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
• Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
• The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis
• Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
• Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
• Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis
• Integrated Cognitive and Neuromotor Rehabilitation in Multiple Sclerosis: A Pragmatic Study
• The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests
• Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
• Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery
• Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
• Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
• Multiple Sclerosis Progression and Relapse Activity in Children
• Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis
• [Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register]
• Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis
• Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
• Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
• Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
• Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
• Multiple sclerosis from onset to secondary progression: a 30-year Italian register study
• Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis
• Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective
• A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study
• Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis
• Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
• Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
• Prognostic indicators in pediatric clinically isolated syndrome
• Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis
• Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors
• Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
• Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
• Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
• Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register
• Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
• Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
• Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
• Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
• Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register
• Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project
• PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
• Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
• Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study
• Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register
• Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, sex, and education
• Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy
• Assessing disability and relapses in multiple sclerosis on tele-neurology
• Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis
• ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis
• Social Media and Multiple Sclerosis in the Posttruth Age
• Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis
• Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression
• COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management
• Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients
• The Dress: Transforming a web viral event into a scientific survey
• Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak
• Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study